Managing RLS in Patients Taking SSRIs
If a patient on an SSRI develops restless legs syndrome, first discontinue or switch the SSRI to a non-serotonergic antidepressant like bupropion, then treat the RLS with gabapentin, pregabalin, or gabapentin enacarbil as first-line therapy, while checking and correcting iron status.
Step 1: Address the SSRI as the Causative Agent
SSRIs are well-documented triggers and exacerbators of RLS 1, 2, 3. The mechanism appears related to serotonergic effects on dopaminergic pathways. The most critical first step is to discontinue or switch the offending SSRI 2.
Switching Strategy:
- Switch to bupropion (dopaminergic antidepressant that may actually improve RLS symptoms) 2
- If an SSRI must be continued, sertraline appears to carry the lowest risk among SSRIs due to its dopamine reuptake blocking properties 2
- Vortioxetine may be another option with potentially favorable effects on RLS 4
- Expect symptom improvement within 2-3 days of discontinuation, with complete resolution in 1-3 weeks 1, 2
Common pitfall: Attempting to treat SSRI-induced RLS without addressing the causative medication leads to treatment failure and polypharmacy.
Step 2: Check Iron Status
Before initiating pharmacotherapy, assess iron parameters:
- Ferritin and transferrin saturation (specific thresholds referenced in good practice statements) 5
- If iron deficiency is present, this must be corrected as it independently worsens RLS
Iron Repletion Options:
- IV ferric carboxymaltose (strong recommendation, first choice for IV iron) 5
- Oral ferrous sulfate (conditional recommendation for appropriate iron status) 5
- IV low molecular weight iron dextran or ferumoxytol (conditional recommendations) 5
Step 3: Initiate First-Line Pharmacotherapy
Based on the 2025 AASM guidelines, α2δ calcium channel ligands are now the preferred first-line treatment 5:
Strong Recommendations (First-Line):
- Gabapentin enacarbil (strong recommendation, moderate certainty) 5
- Gabapentin (strong recommendation, moderate certainty) 5
- Pregabalin (strong recommendation, moderate certainty) 5
These agents are superior to dopamine agonists because they avoid the risk of augmentation (worsening of RLS symptoms with long-term dopaminergic therapy), which is the most challenging complication of RLS treatment 6.
Step 4: Avoid Dopamine Agonists as Standard Treatment
The 2025 AASM guidelines represent a major shift away from dopamine agonists:
Conditional Recommendations AGAINST Standard Use:
These may only be considered for short-term use in patients who prioritize immediate symptom relief over long-term augmentation risk 5. Given that the RLS is SSRI-induced and potentially reversible, dopamine agonists should be avoided entirely in this population.
Step 5: Alternative and Adjunctive Options
If first-line α2δ ligands are insufficient or contraindicated:
Conditional Recommendations:
- Dipyridamole (conditional recommendation) 5
- Extended-release oxycodone or other opioids for refractory cases (conditional recommendation, moderate certainty) 5
- Bilateral high-frequency peroneal nerve stimulation (conditional recommendation) 5
Key Clinical Considerations
Risk Factors to Address:
- Smoking significantly increases RLS risk in SSRI users 3
- Counsel smoking cessation as part of comprehensive management
Quality of Life Impact:
RLS and antidepressant side effects significantly impair QoL across multiple SF-36 domains 3. This underscores the importance of addressing the causative SSRI rather than simply adding another medication.
Monitoring:
- Reassess symptoms 2-3 days after SSRI discontinuation 1, 2
- If symptoms persist beyond 1-3 weeks despite SSRI discontinuation, the RLS may be primary rather than drug-induced
- Avoid rechallenge with the same SSRI, as symptoms recur rapidly (within 2 days) 1
Medications to Avoid:
The AASM guidelines recommend against several agents that might be considered: